Stay updated on Pembrolizumab in Newly Diagnosed Glioblastoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Newly Diagnosed Glioblastoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Newly Diagnosed Glioblastoma Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    Revision: v3.5.4 was added, replacing the previous Revision: v3.5.3, indicating a minor update to the study record on the page.
    Difference
    0.1%
    Check dated 2026-05-15T23:57:00.000Z thumbnail image
  4. Check
    29 days ago
    No Change Detected
  5. Check
    36 days ago
    Change Detected
    Summary
    No additions or deletions are detected in the supplied change data for this study page.
    Difference
    0.1%
    Check dated 2026-05-01T20:22:12.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    The page footer software revision was updated from **v3.5.2** to **v3.5.3**.
    Difference
    0.1%
    Check dated 2026-04-24T16:45:45.000Z thumbnail image
  7. Check
    50 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.1%
    Check dated 2026-04-17T13:38:14.000Z thumbnail image
  8. Check
    79 days ago
    Change Detected
    Summary
    Revision indicator updated from v3.4.3 to v3.5.0.
    Difference
    0.1%
    Check dated 2026-03-19T21:23:00.000Z thumbnail image
  9. Check
    86 days ago
    Change Detected
    Summary
    The page shows an updated revision version from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-12T19:36:27.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Newly Diagnosed Glioblastoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Newly Diagnosed Glioblastoma Clinical Trial page.